A phase 1 trial of the MEK1/2 inhibitor AZD6244 in combination with thoracic radiotherapy in advanced non-small cell lung cancer (NSCLC).

PK Koh, R Califano, E Dean, Corinne Faivre-Finn, J Kosmin, O Ataman, A Jackson, Fiona Blackhall

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish
Pages (from-to)S33-S34
JournalLung Cancer
Issue numberS1
Publication statusPublished - Jan 2010

Cite this